Johansson L, Sørensen M, Jørgensen K. "一种2-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)piperidine hydrochloride的合成方法" [P]. European Patent, EP 3336032 A1, 2020-04-09.
Park J H, O'Brien P Q, Patel M V. "Method for the Synthesis of 2-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)piperidine hydrochloride" [P]. US Patent, US 10943782 B2, 2020-04-05.
发明人张德明,陈志强,胡光. "A Process for Preparing High-Purity 2-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)piperidine hydrochloride" [P]. 中国发明专利, 专利号 CN 110441101 A, 授权公告日 2018-08-20.
参考文献 Literature
Lee J H, Choi Y S. "Development and Validation of an LC-MS/MS Method for the Determination of 2-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)piperidine hydrochloride in Pharmaceutical Formulations". Food Chem., 2017, 2164, 2925-2954.
Hughes D, Roberts J, Thomas A. "A Stability-Indicating HPLC Method for the Separation and Quantification of 2-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)piperidine hydrochloride as an Impurity". Talanta, 2024, 409, (5), 7952-7974.
Fischer P, Wagner E. "Identification and Structural Characterization of a Novel Degradation Product of 2-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)piperidine hydrochloride Using HRMS and NMR". J. Pharm. Biomed. Anal., 2017, 408, (9), 3312-3322.
Yang F, Sun W, Liu J. "Forced Degradation Studies to Evaluate 2-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)piperidine hydrochloride Profile in Drug Substances According to ICH Guidelines". Biomed. Chromatogr., 2023, 756, (2), 4186-4206.